Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Jagic, D.
Maternal and Fetal Outcome of Pregnancies with Factor V-Leiden – A Retrospective Analysis
Humanmedizin; [ Diplomarbeit ] Graz Medical University; 2015. pp. 66
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Cervar-Zivkovic Mila
- Kolovetsiou-Kreiner Vassiliki
- Altmetrics:
- Abstract:
- Objective: Factor V Leiden- Mutation is an autosomal-dominant inherited defect of the coagulation cascade. It affects about 5% of the population. Compared to the healthy population, heterozygous individuals have a 5- to 10-fold increased risk and homozygous individuals a 50- to 100-fold increased risk for thromboembolic events. Thromboembolisms are often manifested when additional risk factors occur, for example during pregnancy. Aim of this study is to evaluate maternal and fetal outcome of women with factor V Leiden-Mutation dependent on the therapy that women have received during pregnancy. Patients and methods: We reviewed data of 104 pregnant women with Factor V-Leiden Mutation, who were cared throughout pregnancy and delivered in the years 2006 and 2012 at the Department of Obstetrics of the Medical University of Graz. We divided our study collective (n=104) into two groups: 1st group: patients, who received antithrombotic therapy (n= 82, 78.85%) and 2nd group: patients, who were not treated (n=22, 21.15%). Furthermore, depending on the therapy that was applied during current pregnancy, we divided the group of treated women into 3 groups: (1) women, who received LMWH (n=78, 95.12%), (2) women, who received only low-dose aspirin (n=1, 1.21%), and (3) women, who received both of these antithrombotic drugs (n=3, 3.65%). Based on pregnancy complications that were noted, maternal and fetal outcome was evaluated. Results: 1st group: Maternal outcome: 24 women (29.27%) developed pregnancy complications. The most common pregnancy complication was pre-eclampsia (n=5, 55.6%). Fetal outcome: 8 pregnancies (9.76%) were associated with IUGR. Whereby, 5 cases (62.5%) were associated with LWMH, one case was associated with low-dose aspirin, and the remaining 2 cases (25%) were associated with administration of both LWMH and low-dose aspirin. 2nd group: Maternal outcome: 3 women (13.64%) have developed pregnancy complications. Whereby, the case of pregnancy-related venous thromboembolism (n=1, 33.37%) was relevant for our study. Fetal outcome: 3 cases (13.64%) of fetal complications were documented. IUFD appeared only once (33.33%) and the remaining two cases were IUGR (66.67%). Conclusion: The usage of antithrombotic drugs improves maternal outcome, but it has a negative impact on fetal outcome. Further studies should be conducted in order to evaluate the necessity for adjustment of the antithrombotic therapy in women with diagnosed FVL-Mutation.